Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SYBX 
Synlogic Inc (SYBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SYBX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.52% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.50M USD | Price to earnings Ratio 5.64 | 1Y Target Price 1 |
Price to earnings Ratio 5.64 | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 0.52 | 52 Weeks Range 0.90 - 1.88 | Updated Date 06/30/2025 |
52 Weeks Range 0.90 - 1.88 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.07% | Return on Equity (TTM) 19.41% |
Valuation
Trailing PE 5.64 | Forward PE - | Enterprise Value -4590748 | Price to Sales(TTM) 1652.07 |
Enterprise Value -4590748 | Price to Sales(TTM) 1652.07 | ||
Enterprise Value to Revenue 0.35 | Enterprise Value to EBITDA 0.18 | Shares Outstanding 11696100 | Shares Floating 3602752 |
Shares Outstanding 11696100 | Shares Floating 3602752 | ||
Percent Insiders 11.31 | Percent Institutions 64.74 |
Analyst Ratings
Rating 1 | Target Price 1 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Synlogic Inc
Company Overview
History and Background
Synlogic, Inc. is a biotechnology company founded in 2011. It focuses on developing Synthetic Biotic medicines to treat diseases. The company has evolved from a research-driven entity to a clinical-stage biopharmaceutical company.
Core Business Areas
- Synthetic Biotic Medicines: Synlogic develops programmable, living medicines engineered to perform specific functions within the body to treat diseases. Their therapeutic pipeline focuses on metabolic and inflammatory diseases.
Leadership and Structure
Dr. Aoife Brennan is the President and CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- SYNB1934 (Phenylketonuria - PKU): An investigational Synthetic Biotic medicine designed to lower levels of phenylalanine (Phe) in patients with PKU. It is currently in clinical trials. No definitive market share data is available as it is not yet approved. Competitors include BioMarin Pharmaceutical Inc. (BMN).
- SYNB8802 (Enteric Hyperoxaluria): An investigational Synthetic Biotic medicine designed to address enteric hyperoxaluria. It is in clinical development. No market share data is available as it is not yet approved. Competitors include Dicerna Pharmaceuticals (acquired by Novo Nordisk).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The synthetic biology subsector is rapidly growing with increasing potential for treating a wide array of diseases.
Positioning
Synlogic is a pioneer in the field of Synthetic Biotic medicines, differentiating itself through its proprietary platform. Its competitive advantage lies in its ability to engineer microbes with specific therapeutic functions. However, the company's early stage development pipeline presents risks.
Total Addressable Market (TAM)
The TAM for Synlogic's focus areas such as PKU and hyperoxaluria is significant and growing, potentially reaching multi-billion dollars. Synlogic is positioning itself to capture a portion of this market through its novel therapeutic approach.
Upturn SWOT Analysis
Strengths
- Proprietary Synthetic Biotic platform
- Novel approach to treating diseases
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Early stage pipeline
- High R&D costs
- Dependence on clinical trial success
- Limited commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new disease areas
- Positive clinical trial results
- Increased adoption of Synthetic Biotic medicines
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other biotechnology companies
- Patent challenges
Competitors and Market Share
Key Competitors
- BMN
- NVO (post Dicerna acquisition)
Competitive Landscape
Synlogic's advantage lies in its unique Synthetic Biotic platform, but it faces strong competition from established pharmaceutical companies with greater resources and commercial experience.
Growth Trajectory and Initiatives
Historical Growth: Synlogic's growth has been primarily driven by its R&D efforts and clinical trial progress.
Future Projections: Future growth depends on the successful completion of clinical trials and potential partnerships. Analyst estimates vary widely due to the inherent risks in biotech development.
Recent Initiatives: Focus on advancing clinical programs for SYNB1934 and SYNB8802, exploring new therapeutic applications for its platform.
Summary
Synlogic is a promising early-stage biotech company pioneering Synthetic Biotic medicines. Its strengths lie in its innovative platform and experienced team. However, it faces significant risks associated with clinical trial success and competition. The company needs to carefully manage its resources and seek strategic partnerships to maximize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Publicly Available Information
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and is subject to change. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synlogic Inc
Exchange NASDAQ | Headquaters Winchester, MA, United States | ||
IPO Launch date 2015-10-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.synlogictx.com |
Full time employees 1 | Website https://www.synlogictx.com | ||
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.